Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Licenses RNAi Patents from Alnylam to Sell Research Products, Services

NEW YORK, June 9 (GenomeWeb News) - Alnylam Pharmaceutials has licensed its short interfering RNA technology patents to Ambion to provide research products and services, the companies said yesterday.


The non-exclusive license comprises use of the Kreutzer-Limmer patent family, owned by Alnylam, which cover siRNAs and their use to mediate RNA interference in mammalian cells.


Ambion is the fifth research products supplier, and the tenth company in total, to take a license to the patent estate from Alnylam, according to the company. The original Kreutzer-Limmer patent is currently opposed in Europeby a number of companies.